Gerard A Rongen has completed his PhD from Radboud University Medical Center (Radboud UMC) and Post-doctoral studies from University of Toronto and Mount Sinai Hospital, Toronto. He completed his specialty training in Internal Medicine in 2000. In 2011, he was appointed as Professor in Translational Cardiovascular Research at Radboud UMC. He has published more than 100 papers in reputed journals and serves in the executive boards of the Dutch Society for Clinical Pharmacology and the European Association of Clinical Pharmacology and Therapeutics. Gerard A Rongen has completed his PhD from Radboud University Medical Center (Radboud UMC) and Post-doctoral studies from University of Toronto and Mount Sinai Hospital, Toronto. He completed his specialty training in Internal Medicine in 2000. In 2011, he was appointed as Professor in Translational Cardiovascular Research at Radboud UMC. He has published more than 100 papers in reputed journals and serves in the executive boards of the Dutch Society for Clinical Pharmacology and the European Association of Clinical Pharmacology and Therapeutics.

Cardiovascular effects of angiogenesis inhibitors